Israel Englander’s Royalty Pharma RPRX Stock Holding History

Israel Englander’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-459,300	Closed	-$14.3M	–	6265
2025 Q1	$14.3M	Buy	459,300 +325,500	+243%	+$10.3M	0.01%	1838
2024 Q4	$3.41M	Sell	133,800 -74,500	-36%	-$1.98M	﹤0.01%	3177
2024 Q3	$5.89M	Buy	208,300 +200,300	+2,504%	+$5.55M	﹤0.01%	2700
2024 Q2	$211K	Hold	8,000	–	–	﹤0.01%	5112
2024 Q1	$243K	Sell	8,000 -13,500	-63%	-$398K	﹤0.01%	5265
2023 Q4	$604K	Sell	21,500 -3,700	-15%	-$102K	﹤0.01%	4526
2023 Q3	$684K	Buy	+25,200	New	+$748K	﹤0.01%	4459
2022 Q3	–	Sell	-16,700	Closed	-$702K	–	7425
2022 Q2	$702K	Buy	+16,700	New	+$685K	﹤0.01%	4692
2021 Q4	–	Sell	-200,000	Closed	-$7.23M	–	7304
2021 Q3	$7.23M	Buy	200,000 +60,000	+43%	+$2.33M	﹤0.01%	2443
2021 Q2	$5.74M	Buy	140,000 +100,000	+250%	+$4.25M	﹤0.01%	2571
2021 Q1	$1.75M	Buy	+40,000	New	+$1.9M	﹤0.01%	3659

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's RPRX Position: Q2 2026 in Review

Israel Englander opened a new position in Royalty Pharma (RPRX) in Q2 2026: 12,043 shares worth $675K. The stake represents ﹤0.01% of the portfolio and ranks #4575 among its holdings. This is a return to the name: Israel Englander previously reported a position in RPRX as recently as Q4 2025.

Israel Englander first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $142M in Q1 2024. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Israel Englander held 12,043 shares of Royalty Pharma worth $675K as of Q2 2026.
Royalty Pharma was a new Israel Englander position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4575 holding.
Israel Englander first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
Israel Englander's Royalty Pharma position peaked at $142M in Q1 2024.
640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.